Special 301 Report Highlights Deficiencies In Asia Pacific's Enforcement Of Patent Rights

Singapore is the only Asia Pacific country not to be mentioned in the Office of the United States Trade Representative (USTR)'s 2009 Special 301 Report or the Pharmaceutical Research And Manufacturers Of America (PhRMA)'s preceding submission to the publication. Infringements of intellectual property rights in the city-state are rare and market access for innovative medicine is generally unhindered.

To read the full article, please choose one of the following options: